BI Asset Management Fondsmaeglerselskab A S Has $20.43 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

BI Asset Management Fondsmaeglerselskab A S boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 45.1% in the fourth quarter, Holdings Channel reports. The firm owned 427,207 shares of the biopharmaceutical company’s stock after purchasing an additional 132,795 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Halozyme Therapeutics were worth $20,425,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock worth $634,999,000 after acquiring an additional 386,618 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Halozyme Therapeutics by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock valued at $92,446,000 after buying an additional 47,795 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock valued at $85,254,000 after buying an additional 9,780 shares in the last quarter. Norges Bank acquired a new position in Halozyme Therapeutics during the fourth quarter worth $60,054,000. Finally, Arrowstreet Capital Limited Partnership raised its position in Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock worth $47,470,000 after acquiring an additional 581,475 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on HALO. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Benchmark reissued a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $58.79 on Friday. The stock has a 50 day simple moving average of $60.45 and a 200 day simple moving average of $55.02. The stock has a market cap of $7.26 billion, a P/E ratio of 17.14, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1-year low of $37.97 and a 1-year high of $66.00. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.